| 000 | 01759 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250513170653.0 | ||
| 264 | 0 | _c19990618 | |
| 008 | 199906s 0 0 eng d | ||
| 022 | _a0306-5251 | ||
| 024 | 7 |
_a10.1046/j.1365-2125.1999.00846.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBeggs, P W | |
| 245 | 0 | 0 |
_aA comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP). _h[electronic resource] |
| 260 |
_bBritish journal of clinical pharmacology _cJan 1999 |
||
| 300 |
_a99-104 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aBezafibrate _xadverse effects |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aComorbidity |
| 650 | 0 | 4 | _aDiabetes Complications |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGemfibrozil _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypertension _xcomplications |
| 650 | 0 | 4 |
_aLipids _xblood |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMyocardial Ischemia _xprevention & control |
| 650 | 0 | 4 | _aNew Zealand |
| 650 | 0 | 4 | _aPractice Patterns, Physicians' |
| 650 | 0 | 4 |
_aProduct Surveillance, Postmarketing _xmethods |
| 650 | 0 | 4 | _aRandom Allocation |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aSimvastatin _xadverse effects |
| 650 | 0 | 4 | _aSurveys and Questionnaires |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aClark, D W | |
| 700 | 1 | _aWilliams, S M | |
| 700 | 1 | _aCoulter, D M | |
| 773 | 0 |
_tBritish journal of clinical pharmacology _gvol. 47 _gno. 1 _gp. 99-104 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1046/j.1365-2125.1999.00846.x _zAvailable from publisher's website |
| 999 |
_c10033716 _d10033716 |
||